Rheumatology

October 14, 2021

Approximately a third of systemic lupus erythematosus patients experience ocular involvement, which may be linked to disease pathophysiology.

October 13, 2021

Investigators analyzed the potential beneficial effect of hydroxychloroquine to prevent COVID-19 infection in patients with rheumatic disease.

October 13, 2021

“Considering medical appointments, laboratory tests, medications, and indirect costs, juvenile idiopathic arthritis generates elevated costs, which results in a high economic impact for the family,” investigators stated.

October 12, 2021

The post hoc analyses evaluated health-related quality of life and efficacy across 4 subgroups treated with either ixekizumab or adalimumab.

October 11, 2021

The Fast-Track Clinic reduced hospitalization rates for patients with polymyalgia rheumatica, which is helpful as symptoms of PMR can mimic other diseases, leading to hospitalization to rule out other conditions.

October 08, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 8, 2021.

October 07, 2021

Limited information is available on the overall disease burden of axial spondyloarthritis (axSpA) in women, as they are generally underrepresented in clinical studies.

October 07, 2021

Veena Joy, MS, discusses Thermo Scientific’s recent FDA approval of their EliA SmDP-S test, which aides in the diagnosis of Systemic Lupus Erythematosus (SLE).

October 05, 2021

“Many patients with axial spondyloarthritis who receive treatment still experience disease-related burdens in different aspects of health-related quality of life,” investigators stated.

October 05, 2021

Few data exist for the use of golimumab in patients whose uveitis does not respond to adalimumab, a first-line biologic choice in refractory juvenile idiopathic arthritis-associated uveitis.